CAP TODAY Pathology/Laboratory Medicine/Laboratory Management
July 29, 2019–Exact Sciences and Genomic Health announced today that the companies have entered into a definitive agreement in which Exact Sciences will combine with Genomic Health for $2.8 billion. The two companies will create a worldwide cancer diagnostics company, joining its two brands Cologuard and Oncotype DX, respectively. The combined company expects to generate revenue of approximately $1.6 billion and gross profit of approximately $1.2 billion in 2020.
Read More »